COLONOSCOPY PREP BAG AND METHODS OF USE
20170290740 · 2017-10-12
Assignee
Inventors
Cpc classification
A61K33/04
HUMAN NECESSITIES
A61K47/34
HUMAN NECESSITIES
A61K33/04
HUMAN NECESSITIES
A61J1/18
HUMAN NECESSITIES
A61K47/10
HUMAN NECESSITIES
B65D75/008
PERFORMING OPERATIONS; TRANSPORTING
A61K9/0095
HUMAN NECESSITIES
A61K33/00
HUMAN NECESSITIES
B65D75/566
PERFORMING OPERATIONS; TRANSPORTING
B65D75/5883
PERFORMING OPERATIONS; TRANSPORTING
A61K33/00
HUMAN NECESSITIES
A61K9/0053
HUMAN NECESSITIES
A61J1/1468
HUMAN NECESSITIES
A61K2300/00
HUMAN NECESSITIES
A61K2300/00
HUMAN NECESSITIES
International classification
A61J1/18
HUMAN NECESSITIES
A61K9/00
HUMAN NECESSITIES
B65D75/56
PERFORMING OPERATIONS; TRANSPORTING
B65D75/00
PERFORMING OPERATIONS; TRANSPORTING
B65D75/58
PERFORMING OPERATIONS; TRANSPORTING
A61K33/00
HUMAN NECESSITIES
A61K33/04
HUMAN NECESSITIES
Abstract
The invention relates to a pharmaceutical composition of polyethylene glycol in solid powder form contained within a polymer bag having an opening. The invention also provides a method for administering a pharmaceutical composition of polyethylene glycol in solid powder form. The method includes providing a polymer bag containing the pharmaceutical composition of polyethylene glycol and adding a fluid to the bag. The polymer bag has a threaded spout and a cap threadably mountable to the spout. The threaded spout forms a passageway to an interior volume of the bag.
Claims
1. A pharmaceutical composition comprising a colonoscopic bowel preparation in solid powder form contained within a polymer bag having an opening.
2. The pharmaceutical composition of claim 1, wherein the pharmaceutical composition comprises polyethylene glycol 3350, potassium chloride, sodium bicarbonate sodium chloride, and, optionally, sodium sulfate anhydrous.
3. The pharmaceutical composition of claim 2, wherein the pharmaceutical composition comprises about 200 to 250 grams of polyethylene glycol 3350, 2.5 to 3.5 grams of potassium chloride, 6.5 to 7.5 grams of sodium bicarbonate and 5.5 to 6.5 grams of sodium chloride.
4. The pharmaceutical composition of claim 3, wherein the pharmaceutical composition is comprises about 236 grams of polyethylene glycol 3350, about 2.97 grams of potassium chloride, about 6.74 grams of sodium bicarbonate and about 5.86 grams of sodium chloride.
5. The pharmaceutical composition of claim 1, wherein the polymer bag comprises high density polyethylene.
6. The pharmaceutical composition of claim 1, wherein the polymer bag has a volume of approximately 4 liters when filled with fluid.
7. The pharmaceutical composition of claim 1, wherein the polymer bag includes at least one opening through the bag, the opening in the bag being defined by a continuous edge of the polymer bag forming a seal between an interior volume of the bag and the opening through the bag.
8. The pharmaceutical composition of claim 1, wherein the opening comprises a threaded spout and a cap threadably mountable to the spout, wherein the threaded spout forms a passageway to an interior volume of the bag.
9. The pharmaceutical composition of claim 1, wherein the bag contains a base.
10. The pharmaceutical composition of claim 1, wherein the polymer bag is a clear polymer material.
11. The pharmaceutical composition of claim 1, wherein the polymer bag includes one or more fill markings on the bag.
12. A method for administering a pharmaceutical composition comprising a colonoscopic bowel preparation in solid powder form, the method comprising: obtaining a polymer bag having a threaded spout and a cap threadably mountable to the spout, wherein the threaded spout forms a passageway to an interior volume of the bag, the pharmaceutical composition in the bag comprising a solid powder; and adding a fluid to the bag.
13. The method of claim 12, further comprising mixing the solid powder with the fluid to dissolve the solid powder.
14. The method of claim 12, wherein approximately four liters of fluid are added to the bag.
15. The method of claim 13, wherein a first portion of the fluid is added to the bag until a mark on a surface of the bag is reached, the bag is shaken to mix the pharmaceutical composition with the fluid, and then a second portion of the fluid is added to the bag.
16. The method of claim 12, wherein the pharmaceutical composition comprises polyethylene glycol 3350, potassium chloride, sodium bicarbonate, sodium chloride and, optionally, sodium sulfate anhydrous.
17. The method of claim 16, wherein the pharmaceutical composition comprises about 200 to 250 grams of polyethylene glycol 3350, 2.5 to 3.5 grams of potassium chloride, 6.5 to 7.5 grams of sodium bicarbonate and 5.5 to 6.5 grams of sodium chloride.
18. The method of claim 12, wherein the polymer bag is a clear polymer material.
19. The method of claim 12, wherein the polymer bag comprises high density polyethylene.
20. A kit for administering a pharmaceutical composition comprising a colonoscopic bowel preparation in solid powder form, the kit comprising: a polymer bag having a threaded spout and a cap threadably mountable to the spout, wherein the threaded spout forms a passageway to an interior volume of the bag; an optional flavour packet; and instructions for administering the pharmaceutical composition comprising adding a fluid to the bag.
Description
DESCRIPTION OF THE DRAWINGS
[0018]
[0019]
[0020]
[0021]
[0022]
[0023]
[0024]
[0025]
[0026]
[0027]
[0028]
[0029]
[0030]
DETAILED DESCRIPTION OF THE INVENTION
[0031] The inventor has determined that a number of problems exist with the current method of providing the colonoscopy prep material in a jug. First, the volume occupied by the jug is approximately four liters yet this jug is supplied to the pharmacist with less than 300 grams of solid power within the jug, which leaves the vast majority of the jug empty. As a consequence the transport of the jug is inefficient with the majority of the load transported being air within the almost empty jug.
[0032] Second, the inventor has also determined that individuals often have difficulties in preparing the mixture. For example, the individual may add insufficient quantities of water with the result being a lumpy mass that has problems dissolving in the water. This problem in reconstitution may be addressed by adding a first quantity of water sufficient to dissolve the entire power mixture and then adding a second quantity of water to result in four liters of fluid. Markings on the container in which the powder is reconstituted may provide sufficient guidance to accomplish this.
[0033] Third, the inventor has determined that individuals have difficulties in preparing the mixture because it is not possible to clearly determine whether or not the solid powder has sufficiently dissolved in the fluid. The walls of the reconstitution jug are relatively opaque such that it is not possible to visually ensure that the solid powder is completely dissolved.
[0034] The inventor has determined that one means of addressing each of these problems with the current reconstitution jug is use of a clear reconstitution bag, also known as a Marsupial Pouch™. Referring to
[0035] The side walls 105 are made from a clear, pharmaceutically acceptable polymer such as, for example, high density polyethylene, that is free of an opacifying agent or colorant. In particular, if the polyethylene polymer contains an opacifying agent or colorant, the amount of the opacifying agent or colorant should be present in an amount that is less than the amount that causes enough opacity such that it is difficult to determine whether or not a mixture of polyethylene glycol powder and water has sufficiently dissolved the powder. In one embodiment, one side wall may be free of an opacifying agent or colorant and the opposite side wall may include an opacifying agent or colorant. In this manner, the individual will have the ability to look through a side wall and determine that the solid material has sufficiently dissolved in the fluid.
[0036] The material making up side walls 105 and the rest of the reconstitution bag may be formed of a single layer or a multiple layer polymeric film. Also, in principle, any such film grade polymeric resin or material as generally known in the art of packaging can be employed. Preferably, a multilayer polymeric film structure is to be employed. Typically the multilayer polymeric sheet will involve at least three categorical layers including, but not limited to, an outermost structural layer, an inner barrier layer, and an innermost layer making contact with and compatible with the intended contents of the bag and capable of forming the necessary seals (e.g. most preferably heat-sealable) to itself. Other layers may also be present to serve as adhesive or “tie” layers to help bond these layers together.
[0037] The outermost structural layer is typically oriented polyester or oriented polypropylene, but can also include oriented polyamide (nylon) or paper or foil. This layer preferably is advantageously unaffected by the sealing temperatures used to make the package, since the package is sealed through the entire thickness of the multilayer structure. The thickness of this layer is typically selected to control the stiffness of the pouch, and may range from about 1 micron to about 100 microns, more preferably between about 5 to about 50 microns, and most preferably from about 8 to about 40 microns. Preferably, a BON (biaxially oriented nylon) film or any other kind of film that imparts flexibility and strong tear characteristics to the film is used for this layer.
[0038] The inner barrier layer(s) and the innermost layer which makes contact with the contents of the bag is preferably a polyethylene film which may be either high density or low density, having a thickness of between about 10 to about 500 microns, more preferably between about 20 to about 300 microns and most preferably between about 50 and about 200 microns. In one particular embodiment, a HDPE and a LDPE are employed together, with the HDPE having a thickness of between 50 and 200 microns, and the LDPE having a thickness of about 10 to about 50 microns.
[0039] An additional primer layer may be used in conjunction with the multilayer structure as is known in the art. The total thickness of the material making up side walls 105 and the remainder of the bag may have a thickness of about 10 microns to about 1,000 microns.
[0040] The threaded spout 115 may be made from a pharmaceutically acceptable polymer such as, for example, high density polyethylene. The polymer used in the spout may be free of an opacifying agent or a colorant, or both. The avoidance of an opacifying agent or colorant in the threaded spout is less important than in the side walls 105 because there is no reason to view through the spout.
[0041] An inside or outside portion of the spout preferably includes a seal 150 to prevent tampering with the interior contents as well as to prevent the introduction of humidity and bacteria to the interior contents of the bag 100. The seal is preferably a foil seal and is made up of one or more layers which are adhered to each other. For example, the seal may be made up of a laminated material consisting of a layer of pulp which is wax mounted to a layer of aluminum foil. The aluminum foil may then be heated to a temperature in the range of about 150-300 degrees Farenheit resulting in melting of the laminating wax between the pulp and foil.
[0042] Alternatively, one or more layers of the seal consist of aluminium foil bonded to a thermoplastic heat seal layer such as a layer of HDPE or LDPE (high-density or low-density polyethylene), the thermoplastic heat seal layer being sealed to the opening of the spout by its melting caused by inductive heating of the aluminium foil.
[0043] The heat seal layer and foil layer may have a thickness of about 0.001 mm to about 1 mm. The seal 150 may additionally include a PET (polyethylene terephthalate) layer having a thickness of about 0.001 mm to about 1 mm. A backing layer and wax layer may also be included, having a combined thickness of about 0.001 mm to about 3 mm.
[0044] The cap 120 may be made from a pharmaceutically acceptable polymer such as, for example, polypropylene. The polymer used in the cap may be free of an opacifying agent or a colorant, or both. The avoidance of an opacifying agent or colorant in the cap is less important than in the side walls 105 because there is no reason to view through the cap.
[0045] A spout fitment (not shown) may be used in conjunction with the spout 115 or spout 154 shown in
[0046] Referring to
[0047] Next, the threaded spout 115 is sealed between a section of the remaining open end between the two opposite sheets. The sealing operation may result in sealed sections of the end on opposite sides of the spout. Referring to
[0048] Referring to
[0049] Referring also to
[0050] The reconstitution bag 100 may additionally include a tap and gland 151 near the base of the bag to aid in dispensing of the suspension which must be consumed by a patient. The tap and gland 151 is shown in
[0051] The tap body including wings is preferably integrally molded from a thermoplastic resin such as polyethylene or polypropylene, but can be molded from numerous materials such as rigid polyurethane, acetal, polyphenylene oxide, polyester, polyamide, polyphenylene sulphide, polyethylene terephthalate, ABS, polycarbonate, and polysulphone. Numerous criteria are considered when choosing a polymer such as cost, ease of molding, oxygen permeability, flexibility, strength, chemical resistance, and operational temperature. Polyolefins such as polypropylene and polyethylene are commonly used for similar types of single-method dispensing taps. It is of particular interest that a material be chosen for its structural behavior at cooler temperatures due to the recommendation to cool down the bowel prep composition prior to administration. Of particular preference for the tap body is a polypropylene/ethylene heterophasic copolymer. Of particular preference for the wings 153A and 153B is polyethylene resin such as that which is manufactured by Safripol and given the trade name Safrene® D 7255.
[0052] The gland is typically made from LDPE or HDPE and may be injection molded, blow molded, extruded or the like. Of particular use is linear low-density polyethylene (LLDPE) such as that which is manufactured by SABIC® including SABIC® LLDPE M200024 00900.
[0053]
[0054]
[0055] The material used to form either child restraint caps 160 or 170 should be a durable yet flexible plastic due to the requirement constant compression of the V shaped portions 161 and 173, respectively. LDPE is one such preferred material.
[0056] The child restrain locks are considered to be a particularly important feature of the reconstitution bag of the present invention due to the potentially toxic nature of the contents placed within the bags and extreme circumstances that would result in having the pharmaceutical contents be ingested by an unauthorized/unprescribed user.
[0057]
[0058] The bag 100 may come in kit form and may include a flavour packet and instructions for administration of the pharmaceutical composition, such as adding a fluid such as water to the bag up to the fill line, mixing or shaking the suspension together for a period of time or until the powder composition is dissolved, chilling the suspension, and/or drinking the suspension.
[0059] The resulting bag is suitable for efficient transport to a pharmaceutical manufacturer for filling with a solid, pharmaceutical powder. It is estimated that the empty bags with the spout in place form a volume that is approximately one eighth to one fifteenth of the volume of four liter jugs, one tenth to one fourteenth of the volume of four liter jugs, or one eleventh to one thirteenth of the volume of four liter jugs, or one twelfth of the volume of four liter jugs. This difference in empty volume provides significant savings in transportation and storage costs, along with the associated ecological benefits.
[0060] Referring to
[0061] The filled bags then may be labelled with appropriate labels according to US Food and Drug Administration regulations for pharmaceutical products, packaged with any required instructions, and stored for shipment to pharmacists, pharmaceutical wholesalers and the like who distribute pharmaceutical products. Because of the reduced size of the filled reconstitution bags in comparison to the currently used reconstitution jugs, both the storage and transportation costs are advantageously reduced.
[0062] When a pharmacist receives a prescription for the filled reconstitution bag, the pharmacist typically will add the flavoring agent to the polyethylene glycol mixture and provide the bag to the patient. The patient then may take the bag home and add a clear fluid to the bag through the threaded spout. The mixing instructions may vary. For example, in one embodiment a warm fluid is poured into the bag until the level of the fluid reaches a first fill mark. The cap then is threadably attached to the spout and the bag shaken until the powder mixture is dissolved. Because the side walls of the bag are clear, the user can easily see whether or not the powder is dissolved. The cap then is removed and the remaining volume of the bag filled with the fluid, although cooled rather than warm fluid is used. The bag may include a second fill mark that indicates when the desired total volume of fluid has been added. The cap then is placed on the spout, the filled bag shaken to mix the fluids, and the filled bag then is placed in refrigerated storage until administration.
[0063] In another embodiment, fluid is added to the bag through the open spout until the bag is full of fluid. The cap then is placed on the spout and the bag is shaken until the polyethylene powder is dissolved. The filled bag then is placed in refrigerated storage until administration.
[0064] The above steps are believed to address the three problems addressed above: a bag that occupies a reduced volume that provides for efficient storage and transportation, clear wall or walls of the bag to ensure dissolution of the polyethylene glycol powder mixture, and markings to provide guidance for adding sufficient quantities of fluid to the bag for mixing.
[0065] The patient preparing for the colonoscopy next follows the steps outlined above for using the currently approved jug of propylene glycol for colonoscopy prep. In these steps, the reconstitution bag of the invention may have a number of useful features. First, the openings in the bag may be used as a handle to hold the bag when mixing the ingredients to dissolve the powder and when pouring the fluid contents into a glass. Second, when the bag is full of fluid, the base will expand and form a surface such that the bag will sit upright with the spout at the top.
[0066] It should be understood that “administering” the composition can be understood to mean delivering or causing to be delivered the composition into the body of an individual. For example, “administering” can be understood to mean a healthcare professional prescribing, supervising, or managing the formal taking of the composition by an individual.
[0067] It should be understood that a number of variations of the bag are possible. First, while the fluid-tight section is illustrated as being formed in the shape of a rectangle or square, other shapes are possible. In one alternative embodiment, an edge of the section is at an angle to the outer edge of the bag. Because of the angled seals, there is the reduced likelihood of pockets being formed in the bag that may hold undissolved polyethylene glycol powder.
[0068] Second, the openings in the fluid-tight section may be round, oblong, oval, square, etc. or a combination of two shapes. Further, the area of each opening may be the same or different.
[0069] Varying seal shapes may be used in conjunction with the base of the bag to allow the bag to remain upright when full of fluid. For example,